OTTAWA, July 12 (UPI) -- The global availability of the bladder cancer drug ImmuCyst is being assessed after its Toronto manufacturer had to stop production because of mold problems.
The Health Canada agency said in a release mold was found in the sterile manufacturing area at the Sanofi Pasteur company's Toronto plant and production was halted.
"In light of the manufacturing problems at the Toronto plant, there may be a global impact on the supply of ImmuCyst," the agency said. "Health Canada will continue to consult with its international regulatory counterparts, including the U.S. Food and Drug Administration."
The federal regulator said before any of the existing ImmunoCyst inventory is released, samples from all production batches will be tested.
There is an alternate bladder cancer drug available in Canada, but the agency didn't name it.
In mid-June, Sanofi Pasteur voluntarily recalled all of its Bacille Calmette-Guérin tuberculosis vaccine produced in the same Toronto plant.
The pharmaceutical building experienced a small flood last October which is the likely source for mold, the company said.
|Additional Health News Stories|
TORONTO, May 25 (UPI) --A Canadian man has been charged with sexually assaulting a 9-year-old girl in Toronto more than 20 years ago.
CANNES, France, May 25 (UPI) --A Russian man paid $1.5 million to sit next to Leonardo DiCaprio on the maiden voyage of the Virgin Galactic trip into space.
NEW YORK, May 24 (UPI) --U.S. stock indexes closed mixed on Friday, with the Dow Jones industrial average closing just above break-even on the New York Stock Exchange.